Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Baxter
Express Scripts
Moodys
Medtronic

Last Updated: July 1, 2022

CLINICAL TRIALS PROFILE FOR DIPRIVAN


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Diprivan

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00336882 ↗ Anaesthesia With Propofol Versus Midazolam : Effect on Oxidative Stress in the Brain of Head Trauma Patients Terminated Ministry of Health, France Phase 3 2006-06-01 Severe traumatic brain injury is associated with an increased production of free radicals causing brain damage. First line treatment of these patients aims to maintain cerebral perfusion and includes deep anaesthesia. Propofol has recently shown anti oxidant properties that need to be confirmed when used in these patients. The main objective of this study is to evaluate the effect of propofol compared to midazolam on intra cerebral oxidative stress following severe traumatic brain injury.
NCT00336882 ↗ Anaesthesia With Propofol Versus Midazolam : Effect on Oxidative Stress in the Brain of Head Trauma Patients Terminated Rennes University Hospital Phase 3 2006-06-01 Severe traumatic brain injury is associated with an increased production of free radicals causing brain damage. First line treatment of these patients aims to maintain cerebral perfusion and includes deep anaesthesia. Propofol has recently shown anti oxidant properties that need to be confirmed when used in these patients. The main objective of this study is to evaluate the effect of propofol compared to midazolam on intra cerebral oxidative stress following severe traumatic brain injury.
NCT00390871 ↗ Acute Neurological ICU Sedation Trial (ANIST) Completed Daniel Hanley Phase 2 2005-05-01 Dexmedetomidine (Precedex, Hospira) is a "super" selective alpha2-agonist - 8-10x more avid binding to alpha2 receptors than clonidine - and may have particularly favorable characteristics as a continuous i.v. infusion sedative for critically ill neuroscience patients. Its combination of anxiolysis, analgesia, without undue lethargy may make it an ideal agent where frequent neurological examinations are important. Unclear, however, is whether Precedex is superior to current common i.v. sedation protocols, and if there are any undue concerns of this agent on cerebral physiology and cortical stimulation.
NCT00390871 ↗ Acute Neurological ICU Sedation Trial (ANIST) Completed Johns Hopkins University Phase 2 2005-05-01 Dexmedetomidine (Precedex, Hospira) is a "super" selective alpha2-agonist - 8-10x more avid binding to alpha2 receptors than clonidine - and may have particularly favorable characteristics as a continuous i.v. infusion sedative for critically ill neuroscience patients. Its combination of anxiolysis, analgesia, without undue lethargy may make it an ideal agent where frequent neurological examinations are important. Unclear, however, is whether Precedex is superior to current common i.v. sedation protocols, and if there are any undue concerns of this agent on cerebral physiology and cortical stimulation.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Diprivan

Condition Name

Condition Name for Diprivan
Intervention Trials
Anesthesia 13
Delirium 8
Pain 5
Obesity 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Diprivan
Intervention Trials
Delirium 12
Sleep Apnea Syndromes 7
Sleep Apnea, Obstructive 6
Neoplasms 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Diprivan

Trials by Country

Trials by Country for Diprivan
Location Trials
United States 78
Egypt 9
China 8
Canada 6
Italy 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Diprivan
Location Trials
New York 9
California 9
North Carolina 7
Pennsylvania 6
Texas 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Diprivan

Clinical Trial Phase

Clinical Trial Phase for Diprivan
Clinical Trial Phase Trials
Phase 4 53
Phase 3 14
Phase 2/Phase 3 5
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Diprivan
Clinical Trial Phase Trials
Completed 79
Unknown status 19
Terminated 15
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Diprivan

Sponsor Name

Sponsor Name for Diprivan
Sponsor Trials
Merck Sharp & Dohme Corp. 4
Hospira, Inc. 4
Hospira, now a wholly owned subsidiary of Pfizer 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Diprivan
Sponsor Trials
Other 182
Industry 25
U.S. Fed 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Boehringer Ingelheim
Merck
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.